Glaxosmithkline | GSK - Sales Revenues


Glaxosmithkline reported GBP10.09B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Bausch Health Companies USD 2.5B 300M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Canopy Growth CAD 74.54M 7.86M Dec/2025
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Drreddys Laboratories INR 789.05M 86.48B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
J&J USD 24.1B 500M Mar/2026
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 281.62M 1.82M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Zoetis USD 2.3B 100M Mar/2026